Indoco Remedies Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
Concerns
- Currently loss-making (EPS ₹-10.7)
- Negative return on equity (ROE -9.4%)
- Low capital efficiency (ROCE 1%)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,899 | ₹4.6L Cr | 36.1 | 5.46 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,100 | ₹2.4L Cr | 81.1 | 14.42 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,857 | ₹1.8L Cr | 82.8 | 19.58 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,650 | ₹1.2L Cr | 59.1 | 13.13 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,385 | ₹1.1L Cr | 31.3 | 3.25 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,120 | ₹1.1L Cr | 23 | 4.16 | 21.2 | 21.1 | 0.38 |
| LAURUSLABS Laurus Labs Limited | ₹1,840 | ₹99K Cr | 90.9 | 18.74 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
INDOCO · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 58.75% | 58.72% | 58.76% | 58.76% | 58.80% | 58.90% |
| FII | 1.69% | 1.92% | 1.48% | 1.70% | 1.25% | 1.24% |
| DII | 19.56% | 19.41% | 18.67% | 18.25% | 18.91% | 18.75% |
| Public | 20.00% | 19.92% | 21.07% | 21.27% | 21.02% | 21.02% |
| Others | — | 0.03% | 0.03% | 0.03% | 0.03% | 0.09% |
Latest News
All newsIndo Count reports Q1 FY27 financial results
*Indo Count reports Q1 FY27 financial results.* The company has submitted its financial results for the quarter ended June 30, 2026. Results are in-line with market expectations, with no major surprises. Key metrics include revenue of **₹320 crore** and net profit of **₹28 crore**. 📊 *STOCKS:* $INDOCO | 🏢 *SECTOR:* Textiles | #MEDIUMIMPACT #Earnings
Indoco Remedies reports Q1FY26 financial results
*Indoco Remedies reports Q1FY26 financial results*. Indoco Remedies has announced its financial results for the quarter ended June 30, 2026. The outcome includes key performance metrics and financial standings for the first quarter. Further details on revenue, profit, and guidance will be assessed upon full disclosure. 📊 *STOCKS:* INDOCO | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #earnings
Indoco Remedies to hold shareholder meeting on Sep 17, 2026
*Indoco Remedies to hold shareholder meeting on Sep 17, 2026.* The event is a routine corporate exercise as per regulatory norms. No financial impact is expected from the meeting announcement. It does not indicate any immediate change in business operations or strategy. 📊 *STOCKS:* $INDOCO | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ShareholdersMeeting
Indoco Remedies sets dividend record date for Sept 2026
*Indoco Remedies sets dividend record date for Sept 2026.* The company has fixed **10-Sep-2026** as the record date for dividend distribution. Shareholders registered on or before this date will be eligible. No financial figures disclosed yet. 📊 *STOCKS:* INDOCO | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Dividend
Indo Count to host investor meet for updates.
*Indo Count to host investor meet for updates.* The company has scheduled an analyst and institutional investor meeting to discuss business developments. Such meets typically offer insights into management strategy and recent performance trends. No major announcements expected. 📊 *STOCKS:* $INDOCO | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorMeet
Indo Count to host analyst and investor meet
*Indo Count to host analyst and investor meet* to discuss business updates and strategy. The schedule for the meet is included in the corporate filing. No financial figures or major announcements were disclosed. 📊 *STOCKS:* INDOCO | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorMeet
Indoco Remedies hosts analyst and investor meet
*Indoco Remedies hosts analyst and investor meet.* The company provided updates during its recent analyst and investor call. No major financial figures or strategic shifts were disclosed. The session focused on business performance and market outlook. 📊 *STOCKS:* $INDOCO | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Earnings
Indoco Remedies publishes statutory notice in newspaper
*Indoco Remedies publishes statutory notice in newspaper* as part of regulatory compliance. The filing does not disclose any financial or operational update. Such notices are routine and typically relate to general body meetings or disclosures mandated under law. No immediate market-moving information was revealed. 📊 *STOCKS:* $INDOCO | 🏢 *SECTOR:* Pharma | #LOWIMPACT #CorporateFiling
Indo Count Industries to host analyst meet
*Indo Count Industries to host analyst and institutional investor meet.* Purpose is to provide updates on business and financial performance. No major announcements or data disclosed. Event may offer clarity on near-term outlook. 📊 *STOCKS:* INDOCO | 🏢 *SECTOR:* Pharma | #LOWIMPACT #AnalystMeet
About Indoco Remedies Limited
Indoco Remedies (Indoco) is a Mumbai-based pharmaceutical company that focuses on formulations with a presence in contract manufacturing and research. The Company is engaged in the manufacturing and marketing of pharmaceutical Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).[1]
HealthcarePharmaceuticals & Biotechnology